Buprenorphine in cancer pain

Supportive Care in Cancer

Volumn 13, Issue 11, 2005, Pages 878-887

  Davis, Mellar P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE; BUPRENORPHINE; CARBAMAZEPINE; CLONIDINE; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; FLUVOXAMINE; GAMMA GLUTAMYL HYDROLASE; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; KETOCONAZOLE; MACROLIDE; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NEUROLEPTIC AGENT; NORBUPRENORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PHENOBARBITAL; PHENYTOIN; TILIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

BONE PAIN; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS TOLERANCE; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ERYTHEMA; FATIGUE; HEPATITIS; HUMAN; LIPOPHILICITY; LOW DRUG DOSE; NAUSEA; NEUROTOXICITY; NONHUMAN; OPIOID INDUCED EMESIS; PAIN; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN NECROSIS; SWEAT GLAND DISEASE; TRANSDERMAL PATCH;

ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; NEOPLASMS; PAIN;

EID: 27144543526     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0849-9     Document Type: Review

References (94)

1. Lewis JW, Husbands SM (2004) The orvinols and related opioids - high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10(7):717-732
2. Cowan A (2003) Buprenorphine: new pharmacological aspects. Int J Clin Pract 133(Suppl):3-8
3. Leander JD (1988) Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 151(3):457-461
4. Leander JD (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26(9):1445-1447
5. Pick CG, Peter Y, Schreiber S et al (1997) Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with k3 analgesia. Brain Res 744:41-46
6. Kamei J, Sodeyama M, Tsuda M et al (1997) Antinociceptive effect of buprenorphine in mul-opioid receptor deficient CXBK mice. Life Sci 60(22):333-337
7. Negus SS, Kykstra LA (1988) Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 156(1):77-86
8. Ide S, Minami M, Satoh M et al (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 29(9):1956-1963
9. Recker MD, Higgins GA (2004) The opioid receptor like-1 receptor agonists Ro 64-6198 (1S, 3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8- triaza-spiro [4.5] decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. J Pharmacol Exp Ther 311(2):652-658. DOI 10.1124/jpet.104.071423
10. Robbie DS (1979) Trial of sublingual buprenorphine in cancer pain. Clin Pharmacol 7(Suppl):315S-317S
11. Campora E, Merlini L, Pace M et al (1991) The incidence of narcotic-induced emesis. J Pain Symptom Manage 6(7):428-430
12. De Conno F, Ripamonti C, Sbanotto A et al (1991) A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage 6(7):423-427
13. Kjaer M, Henriksen H, Knudsen J (1982) A comparative study of intra-muscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol 13(4):487-492
14. Ventafridda V, De Conno F, Guarise G et al (1983) Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine. Arzneimittelforschung 33(4):587-590
15. Zenz M, Piepenbrock S, Tryba M et al (1985) Long-term therapy of cancer pain. A controlled study on buprenorphine. Dtsch Med Wochenschr 110(12):448-453
16. Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629-2638
17. Evans HC, Easthope SE (2003) Transdermal buprenorphine. Drugs 63(19):1999-2010
18. Ibrahim RB, Wilson JG, Thorsby ME et al (2000) Effect of buprenorphine on CYP3A activity in rat and human liver. Life Sci 66(14):1293-1298
19. Sporer KA (2004) Buprenorphine: a primer for emergency physicians. Ann Emerg Med 43(5):1-7
20. Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28(11):2000-2009
21. Hou Y, Tan Y, Belcheva MM et al (2004) Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. Brain Res Dev Brain Res 151(1-2):149-157
22. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-luce receptors. J Neurosci 23(32):10331-10337
23. Negus SS, Bidlac JM, Mello NK et al (2002) Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13(7):557-570
24. Johnson RE, Fudala PJ, Payne R (2005) Buprenorphine: considerations for pain management. J Pain Symptom Manage 29(3):297
25. Wallenstein SL, Kaiko RJ, Rogers AG et al (1986) Crossover trials in clinical analgesic assays: studies of buprenorphine and morphine. Pharmacotherapy 6(5):228-235
26. Bulka A, Kouya PF, Bottiger Y et al (2004) Comparison of the antinociceptive effects of morphine, methadone, buprenorphine and codeine in two substrains of Sprague-Dawley rats. Eur J Pharmacol 492:27-34
27. Thomas JM, Hoffman BB (1993) Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells. J Pharamacol Exp Ther 264(1):368-374
28. Shah MV, Jones DI, Rosen M (1986) "Patient demand" postoperative analgesia with buprenorphine. Comparison between sublingual and i.m. administration. Br J Anaesth 58(5):508-511
29. Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E (2005) Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507(1-3):87-98
30. Schuh KJ, Johanson CE (1999) Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56:55-60
31. Tantucci C, Paoletti F, Bruni B et al (1992) Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol 30(6):202-207
32. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94(6):825-834. DOI 10.1093/bja/aeil45
33. Clarot F, Pierre GJ, Vaz E et al (2003) Tramadol-benzodiazepines and buprenorphine-benzodiazepines two potentially fatal cocktails. J Clin Forensic Med 10(2):125-126
34. Kintz P (2002) A new series of 13 buprenorphine-related deaths. Clin Biochem 35(7):513-516
35. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G (2000) Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 45(1):226-228
36. Stock C, Shum JH (2004) Buprenorphine: a new pharmacotherapy for opioid addictions treatment. J Pain Palliat Care Pharmacother 18(3):35-54
37. Gerra G, Borella F, Zaimovic A et al (2004) Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37-45
38. Oreskovich MR, Saxon AJ, Ellis MLK et al (2005) A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77:71-79
39. Roy SD, Roos E, Sharma K (1994) Transdermal delivery of buprenorphine through cadaver skin. J Pharm Sci 83:126-130
40. Berson A, Fau D, Fornacciari R et al (2001 ) Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitocliondrial dysfunction versus metabolic activation. J Hepatol 34:261-269
41. Lasseter KC, Venitz J, Eltahtawy A, Miotto J, Munera C (2001) Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Clin Pharmacol Ther 69:P2 Abstract PI-4
42. Sbrenna S, Marti M, Morari M, Calo' G et al (2000) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol 130(2):425-433
43. Dean AJ, Bell J, Christie MJ et al (2004) Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatr 19:510-513
44. Lindhardt K, Bagger M, Andreasen KH, Bechgaard E (2001) Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. Int J Pharm 217(2):121-126
45. McAleer SD, Mills RJ, Polack T et al (2003) Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend 72:75-83
46. Strain EC, Mood DE, Stoller KB et al (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37-43
47. Nath RP, Upton RA, Everhart ET et al (1999) Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39(6):619-623
48. Zenz M, Piepenbrock S, Tryba M et al (1983) Sublingual buprenorphine tablets: initial clinical experiences in long-term therapy of cancer pain. Fortschr Med 101(5):191-194
49. Harris DS, Mendelson JE, Lin ET et al (2004) Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokinet 43(5):329-340
50. Picard N, Cresteil T, Djebli N, Marquet P (2005) In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 33(5):689-695
51. Lotsch J, Skarke C, Liefhold J et al (2004) Genetic predictors of the clinical response to opioid analgesics. Clin Pharmaocokinet 43(14):983-1013
52. Soars MG, Ring BJ, Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31(6):762-767
53. Green MD, King CD, Mojarrabi B et al (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyl-transferase 1A3. Drug Metab Dispos 26 (6):507-512
54. Williams JA, Hyland R, Jones BC et al (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32(11):1201-1208
55. Kobayashi K, Yamamoto T, Chiba T et al (1998) Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26(8):818-821
56. Umehara K, Shimokawa Y, Miyamoto G (2002) Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 25(5):682-685
57. Zhang W, Ramamoorthy Y, Tyndale RF et al (2003) Interaction of buprenorphine and its metabolite norbuprenorpine with cytochromes P450 in vitro. Drug Metab Dispos 31(6):768-772
58. Umeda S, Harakawa N, Yamamoto M, Ueno K (2005) Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull 28(2):212-216
59. Jones HE, Johnson RE, Jasinki DR, Milio L (2005) Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 78(1):33-38
60. Pasqualucci V, Tantucci C, Paoletti F et al (1987) Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effect and analgesic activity. Pain 29:273-286
61. Budd K (2003) Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract (Suppl) 133:9-14
62. Coffman BL, King CD, Rios GR et al (1998) The glucuronidation of opioids, other xenobiotics, and androgen by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 26(1):73-77
63. Sittl R, Griessinger N, Likar R (2003) Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 25(1):150-168
64. Sorge J, Sittl R (2004) Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26(11):1808-1820
65. Likar R, Griessinger N, Sadjak A et al (2003) Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain. Wien Med Wochenschr 153(13-14):317-322
66. Cone EJ, Gorodetzky CW, Yousefhejad D et al (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12(5):577-581
67. Manzi R, Rizzi M, D'Elia F et al (1991) Use of buprenorphine after right hepatectomy. Minerva Anestesiol 57(6):379-382
68. Radbruch L (2003) Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract (Suppl) 133:19-22
69. Radbruch L, Vielvoye-Kerkmeer A (2003) Buprenorphine TDS: the clinical development rationale and results. Int J Clin Pract (Suppl) 133:15-18
70. Noda J, Umeda S, Arai T et al (1989) Continuous subcutaneous infusion of buprenorphine for cancer pain control. Clin J Pain 5(2):147-152
71. Hashimoto Y, Utsumi T, Tanioka H et al (1991) Epidural buprenorphine or morphine for the relief of head and neck cancer pain. Anesth Prog 38(2):69-71
72. Francaviglia N, Silvestro C, Carta F et al (1990) Subarachnoid buprenorphine administered by implantable micropumps. Acta Neurochir (Wien) 102(1-2):62-68
73. Lari S, Fabbri G, Mattioli R et al (1995) Epidural buprenorphine versus morphine in bone cancer pain. Minerva Anestesiol 51(11-12):609-614
74. Ferrari A, Coccia CPR, Bertolini A et al (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551-559
75. Robertson SA, Taylor PM, Sear JW (2003) Systemic uptake of buprenorphine by cats after oral mucosal administration. Vet Rec 152(22):675-678
76. Iribarne C, Picart D, Dreano Y et al (1998) In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 12:194-199
77. Giroud C, Michaud K, Sporkert F et al (2004) A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry (HILIC-MS). J Anal Toxicol 28(6):464-474
78. Pirnay S, Borron SW, Giudicelli CP et al (2004) A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99(8):978-988
79. Jappinen A, Kokki H, Naaranlahti TJ et al (1999) Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 21(6):272-274
80. Feeney GF, Fairweather P (2003) Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Drug Alcohol Rev 22(3):359-361
81. Bliesener N, Albrecht S, Schwager A et al (2005) Plasma testosterone and sexual function in men on buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 90(1):203-206
82. De Conno F, Panzeri C, Brunelli C et al (2003) Palliative care in a National Cancer Center: results in 1987 vs. 1993 vs. 2000. J Pain Symptom Manage 25(6):499-511
83. Ostrowski MJ, Jacson AW (1979) Intra-muscular buprenorphine-clinical experience in its use for relieving pain due to malignant disease. Br J Clin Pract 33(10):286, 293
84. Taguchi T (1982) Effect of a long-acting analgesic, buprenorphine on cancer pain a single-blind crossover comparison with pentazocine. Gan To Kagaku Ryoho 9(2):250-257
85. Dini D, Fassio T, Gottlieb A et al (1986) Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients. Minerva Med 77(3-4):93-104
86. De Conno F, Ripamonti C, Tamburini M et al (1987) Buprenorphine in cancer pain: cross comparison with pentazocine. Minerva Med 78(15):1177-1181
87. De Conno F, Ripamonti C, Sbanotto A et al (1993) A clinical note on sublingual buprenorphine. J Palliat Care 9(3):44-46
88. Brema F, Pastorino G, Martini MD et al (1996) Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 16(4-5):109-116
89. Bono AV, Cuffari S (1997) Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine. Drugs 53(Suppl 2):40-49
90. Schriek P (2004) Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer 12:882-884
91. PDR (2004) Physicians' desk reference, 58th edn. Thompson, Montvale, NJ, pp 2866-2869
92. Reidenberg B, El-Tahtawy A, Munera C et al (2001) Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for seven days. J Clin Pharmacol 41:1026
93. Reidenberg B, El-Tahtaway A, Munera C et al (2001) Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to seven days. J Clin Pharmacol 41:1027
94. Sittl R, Likar R, Nautrup BP (2005) Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 27(2):225-237